EFFICACY AND SAFETY OF 20% AZELAIC ACID CREAM FOR PAPULO-PUSTULAR ACNE VULGARIS
DOI:
https://doi.org/10.34287/MMT.4(51).2021.1Abstract
Purpose of the study. To determine the safety and efficacy of 20% azelaic acid cream in the treatment of patients with papulopustular acne vulgaris.
Materials and methods. 65 patients with acne vulgaris were examined. The control group consisted of 30 healthy individuals. Acne severity was evaluated according to G. Michaelsson et al. scale, Cook’s scale, absolute number of papules and pustules. Assessment of quality of life was performed. Facial skin microbiocenosis was assessed. All patients with acne vulgaris applied 20% azelaic acid cream during 15 ± 2 days.
Results and discussion. The use of 20% azelaic acid cream contributed to the rapid regression of inflammatory acne. After 10 days of treatment, the number of papulopustular elements decreased in 3 times. After 10 days of therapy acne score according to G. Michaelsson et al. decreased in 1,5 times and after 15 days of treatment – in 1,9 times. After 10 days of therapy the acne score on the Cook’s scale decreased in 1,4 times. At the end of the study the acne score on the Cook’s scale was 2,4 points. There was a significant decrease in the total number of bacteria, the number of coagulase-positive staphylococci, quantity of Propionibacterium acnes on facial skin in 15 days after the start of therapy. A significant difference in the average value of the DLQI was fixed before (18,9 ± 0,31) and at the end (8,1 ± 0,54) of treatment.
Conclusions. The high effectiveness of 20% azelaic acid cream in treatment of papulopustular acne vulgaris was proved. 20% azelaic acid cream provides a rapid regression of inflammatory forms of acne, reduction of total quantity of bacteria and Propionbacterium acnes on skin.
References
Dawson AL, Dellavalle RP. Acne vulgaris. BMJ. 2013 May 8. 346: 2634. doi: 10.1016/S01406736(11)60321-8.
Kelhälä HL, Fyhrquist N, Palatsi R, et al. Isotretinoin treatment reduces acne lesions but not directly lesional acne inflammation. Exp Dermatol. 2016 Jun. 25 (6): 477–8. doi: 10.1111/ exd.12971.
Saluja SS, Walker ML, Summers EM, Tristani-Firouzi P, Smart DR. Safety of non-ablative fractional laser for acne scars within 1 month after treatment with oral isotretinoin: A randomized split-face controlled trial. Lasers Surg Med. 2017 Dec. 49 (10): 886–890. doi: 10.1002/lsm.22711.
Baek JH, Ahn SM, Choi KM, Jung MK, Shin MK, Koh JS. Analysis of comedone, sebum and porphyrin on the face and body for comedogenicity assay. Skin Res Technol. 2016 May. 22 (2): 164–9. DOI: 10.1111/srt.12244.
Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, et al. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome. JAMA Dermatol. 2016 Apr. 152 (4): 391–8. doi: 10.1001/ jamadermatol.2015.4498.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May. 74 (5): 945–973.e33. doi: 10.1016/j.jaad.2015.12.037.
Eichenfield LF, Lain T, Frankel EH, Jones TM, Chang-Lin JE, Berk DR, et al. Efficacy and Safety of Once-Daily Dapsone Gel, 7,5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials. J Drugs Dermatol. 2016 Aug 1. 15 (8): 962–9. https://pubmed.ncbi.nlm.nih.gov/27537997/.
Raoof TJ, Hooper D, Moore A, Zaiac M, Sullivan T, Kircik L, et al. Efficacy and Safety of a Novel Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: A Phase 3 Study. J Am Acad Dermatol. 2019 Jun 1. doi: 10.1016/j.jaad.2019.05.078.
Gold LS, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart IA. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019 Jan. 80 (1): 168–177. doi: 10.1016/j.jaad.2018.08.020.
Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Apr 22. DOI: 10.1001/ jamadermatol.2020.0465.
Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, et al. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. J Drugs Dermatol. 2018 Sep 1. 17 (9): 987–996. https://pubmed.ncbi. nlm.nih.gov/30235387/.
